Novartis Investors Intensify Scrutiny of Acquisition Strategy Following Drug Setbacks
Source Summary
Novartis investors are increasing their scrutiny of the company's mergers and acquisitions strategy following setbacks to drugs the company acquired through dealmaking. The investor concern reflects broader questions about the effectiveness of Novartis's M&A approach.
Why it matters
Investor scrutiny of M&A strategy directly affects shareholder confidence and may influence Novartis's future dealmaking decisions and capital allocation.
